The REVOLENS study was one of only two STIC projects selected by the Ministry of Health for funding in 2012, and the first in the field of emphysema treatment since 2006. The French Government committed to pay 1.3 Million Euros ($1.8 Million) to support this study.
The RePneu LVRC System is a minimally invasive device intended to improve lung function, exercise capacity and quality of life in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress diseased tissue, restore elastic recoil, and re-tension the airway network. The RePneu LVRC treatment has proven to be effective for a broad range of emphysema patients without requiring any complex diagnostic evaluation. The RePneu Coil does not block airways, prevent distal access, or destroy lung tissue, but instead provides a simple mechanical solution designed both to treat the key physiologic effects of emphysema and to overcome the key challenges of emphysema treatment. The RePneu LVRC has proven effective in treating patients with both heterogeneous and homogeneous emphysema, in both upper and lower lobes, and in patients with Residual Volume of 175% predicted and above. In addition, the RePneu LVRC works independently of collateral ventilation, and is performed in a gentle, well-tolerated procedure with a rapid recovery period.
The RePneu LVRC, which is undergoing a clinical pivotal trial in the United States, has a CE Mark and has been used in over 1500 procedures worldwide, even though the device has been comm
|SOURCE PneumRx, Inc.|
Copyright©2012 PR Newswire.
All rights reserved